AMRX - Amneal Reports Q4 and FY 2023 Financial Results

2024-03-01 07:27:26 ET

DENVER, Colo., Mar 01, 2024 ( 247marketnews.com )- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX ) reported its fourth quarter and full year 2023 financial results, this morning.

Its full year 2023 net revenue was $2.39 billion and projects 2024 financial guidance of $2.55 to $2.65 billion in net revenue

Its adjusted 2023 EBITDA was $558 million and projected $580 to $620 million in adjusted 2024 EBITDA.

AMRX is trading at $6.15, up $0.65 (+11.41%), on 696.02K shares.

“Amneal had a very successful year in 2023 as we delivered strong execution and growth across our diversified pharmaceutical business. We are starting 2024 with substantial momentum and key catalysts, including complex high-value products, biosimilars and specialty, to further expand our reach. Against the macro backdrop of a global aging population, significant unmet patient needs and ongoing supply issues, Amneal’s mission to provide access to high-quality, affordable, essential medicines has never been more important or more aligned with industry dynamics. Our durable business is ideally positioned to drive sustainable, profitable growth and create value for all our stakeholders, this year and beyond,” said Chirag and Chintu Patel, Co-Chief Executive Officers.

The post Amneal Reports Q4 and FY 2023 Financial Results appeared first on 24/7 MarketNews .

For further details see: